medical devices single audit program (mdsap) pilot program
Post on 02-Jan-2017
223 Views
Preview:
TRANSCRIPT
Medical Devices Single Audit Program MDSAP - Overview and Update
Keith M Smith Senior Adviser and MDSAP Assessor Quality Audits and Assessments Section Medical Devices Branch Medical Devices and Product Quality Division ARCS Scientific Congress Canberra, August, 2016
Objectives • TGA’s International Programs
• IMDRF MDSAP Model • MDSAP Pilot • Audits • Assessments • Implementation • Participation • Questions
1
TGA’s International Programs • Seeking to collaborate with other Regulators in innovative ways
– Share resources and the regulatory work – Leverage external resources and systems – Converge requirements and expectations – Build consistency and confidence in outcomes
• The MDSAP is a significant international program! … we envisage … – Benefits manufacturers through a reduced number of audits, reduced annual cost, an increase
in the predictability of outcomes, and opportunities for export markets. – Benefits Sponsors as an additional basis for market authorisation. (ARTG entry) – Benefits Regulators as it frees resources to target risk areas
2
IMDRF MDSAP Model
3
MDSAP model • Allows recognized Auditing Organisations to conduct audits of a medical device
manufacturer that will satisfy the relevant Quality Management System requirements of multiple participating Regulatory Authorities.
• Referred to as a “single” audit program
• Started development in 2012 by the International Medical Device Regulators Forum (IMDRF) – Successor of the Global Harmonisation Task Force – Australia, Brazil, Canada, China, Europe, Japan, Russia, and the United States of America
4
CONCEPT
Regulatory Authorities
Assess and recognize Share audit
report and certificate
Make regulatory decisions – Market Authorisation
Auditing Organisations Audit and certify
Medical Device Manufacturers
5
MDSAP Pilot
6
MDSAP Pilot • International consortium of some of the countries who are members of the IMDRF
who are dedicated to pooling technology, resources, and services to improve the safety and oversight of medical devices on an international scale in an Audit and Assessment Pilot Program – Memorandum of Understanding, Brazil, November 2012
• MDSAP Pilot – January 2014 – December 2016
7
MDSAP Pilot - International Consortium
• MDSAP international consortium of countries: – Therapeutic Goods Administration (TGA) of Australia, – Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA), – Health Canada, – Japanese MHLW and PMDA, and – U.S. Food and Drug Administration (US FDA)
• Observers – World Health Organisation (WHO) Diagnostic Prequalification Program – European Union May make a decision about full participation later in 2016
8
MDSAP Pilot – Governance and Operations
• Regulatory Authority Council (RAC)
• International Subject Matter Expert (SME) Working Groups
9
Regulatory Authority Council (RAC) • The MDSAP governing body is the RAC
– Two senior managers from each participating jurisdiction – Representation from observing jurisdictions (WHO and EU)
• Responsibilities: – Perform executive planning, strategic priorities, sets policy and make final decisions on behalf of
the MDSAP Consortium. – Final review and approval of MDSAP documentation; policy, procedures, work instructions, etc. – Auditing Organisation authorisation and recognition decisions
10
Subject matter expert (SME) working groups
• MDSAP Audit and Assessment SME – Develops procedures, work flows, work instructions, templates, training, etc. for The auditing of medical device manufacturers by recognized Auditing Organisations The assessment of Auditing Organisations by Regulatory Authorities A Quality Management System for the operation of the MDSAP
• Regulatory Exchange Platform secure (REPs) SME – Developed IT requirements and specifications for REPsecure – Overseeing the Cooperative Agreements with the Host Organisation Pan American Health Organisation (PAHO)
11
MDSAP Audits by Auditing Organisations
12
MDSAP Audit Process: Model and Criteria • The design of each layer of the MDSAP seeks to define relevant objectives,
processes, competence management requirements and outputs.
• The audit process for medical device manufacturers provides for an efficient and thorough coverage of each QMS process requirement – Documented in an “Audit Model” and “Companion Guide” – Defines a prescribed audit “process” approach – The sequence of the audit of QMS processes ensures information determined early in the audit
informs the audit of processes later in the audit. – Annual audits
13
MDSAP Audit Process: Model and Criteria • Each QMS process has objectives and a series of tasks to determine compliance
with ISO13485 and Regulatory requirements.
• Regulatory requirements include, for example: – Registration of manufacturing sites – Licensing of medical devices – Reporting of adverse event and advisory notices (recalls) – Tracking of specified devices – Review of technical documentation in the context of audit
14
MDSAP audit process: Model and criteria
• An Auditing Organisation’s activities are directed by a number of documents, for example: – Audit Model and Companion Guide – Nonconformity Grading and RA Exchange Form and Guide – Audit Report Template and Policy / Guide – Audit Time Calculations – Post Audit Timeline – Certification document content – Notification of manufacturer participation, etc
• Full process is defined in “MDSAP Audit Procedures and Forms” – Web search “FDA MDSAP Pilot” for the complete listing
15
MDSAP audit model
- Sequence to audit QMS processes for ISO 13485 and Regulatory Requirements
ent
anag
emM
ksiR
ngiha
sc
urP
Management
Measurement, Analysis and Improvement
Device Marketing Authorisation and
Facility Registration
Measurement, Analysis and Improvement
MD Adverse Events and Advisory Notice
Reporting
Design and Development
Device Marketing Authorisation and
Facility Registration
Production and Service Controls
16
Nonconformity grading • GHTF N19 - Nonconformity
Grading System for Regulatory Purposes
• NCs are assigned a grade, 1 to 5 • Calculated in two steps
– Grading Matrix – Escalation Rules No Documented Process, +1 Release of nonconforming medical
device, +1
First Repeat
3 4
1 2 Occurrence
Impa
ct
Indi
rect
Cl 4
.1 –
6.3
D
irect
Cl 6
.4 –
8.5
.3
17
Post audit timeline • 5 Working Day Notification
– Auditing Organisation informs MDSAP Regulatory Authorities of 1 or more Grade 5 Nonconformities, or >2 Grade 4 Nonconformities, or public health threat/fraud
• 15 Calendar Days – Medical Device manufacturer provides remediation plan
• 30 Calendar Days – Medical Device manufacturer provides evidence of implementation of remediation actions for
any grade 4 or 5 nonconformities • 45 or 90 Calendar Days
– Auditing Organisations submits full audit report package – 45 days in cases where a 5 day notification was required.
18
MDSAP – Manufacturer Audit Program
t ud
iA Initial Audit Surveillance Audit Recertification Audit
Special Audit, Unannounced Audit, Regulatory Authority audit
Stage 1 Stage 1 – (as needed) Stage 1 – (as needed)
s Documentation Review Documentation Review Documentation Review
ieitivtcA t Review audit reports, Stage 2 Review of changes,
udi corrections/corrective
A On-Site Full Audit management process, actions, tasks not M,A&I, registration, covered in previous authorisation, etc. audits 19
MDSAP Assessments by Regulatory Authorities
20
MDSAP Auditing Organisation Assessment Criteria
• An MDSAP Assessment is based on the model established by the IMDRF MDSAP documents that refer to the relevant ISO Standard, primarily … – ISO/IEC 17021:2011 – Reqs for bodies providing audit and certification of management systems – N3 – Requirements for Auditing Organisations – N5 – Regulatory Authority assessment method – N11 – Auditing Organisation Nonconformity Grading and Decision Process – … includes verification that AOs are auditing regulatory requirements
• Full process is defined in “MDSAP Assessment Procedures and Forms” – Application, Assessment, Decision Making etc. – Web search “FDA MDSAP Pilot” for the complete listing
21
RA assessment method: Processes
Outsourcing
• Management (including Impartiality)
• Measurement, Analysis and Improvement
• Competency Management
• Audit and Certification Process
• Information Management
22
A
sses
smen
t MDSAP – Auditing Organisation Assessment Program
Initial Assessment
Application Review
Stage 1 Assessment including Documentation Review
Stage 2 On-Site Assessment (Head Office)
3 Witnessed Audits
Surveillance Assessment Re-Recognition Assessment
On-Site Assessment of all Critical Locations
(as necessary)
Surveillance On-Site Assessment (Head Office)
1 Witnessed Audit
1 Witnessed Audit per Critical Location per Assessment
Cycle (as necessary)
Stage 1 Assessment including Documentation
Review for changes
Re-Recognition On-Site Assessment (Head Office)
1 Witnessed Audit
1 Witnessed Audit per Critical Location per Assessment
Cycle (as necessary)
Asse
ssm
ent A
ctiv
ities
23
Summary: Assessment versus audit Assessment and Recognition • of Auditing Organisation
by Regulatory Authorities • of compliance to the IMDRF
Recognition Criteria – ISO/IEC 17021, IMDRF N3, N5, N11
etc, GHTF N19
• 4-year cycle • MDSAP Assessment Model
Audits and Certification • of Medical Device manufacturers
by Auditing Organisation • of compliance to ISO 13485, plus specific
quality system requirements from the participating RAs’ regulations
• 3-year cycle • MDSAP Audit Model
24
MDSAP Implementation
25
Timeline
IMDRF Model and Pilot
Development
CMDCAS Registrar
Assessment / Witness Audits
ISO13485:2003 to 2016,
CMDCAS to MDSAP
Global System??
26
Auditing organisations and the MDSAP Pilot • Stages of Assessment
– Application Review – Stage 1 - Documentation Review – Stage 2 - Head Office and Critical Location on-site assessments – When any nonconformities have been closed the AO is “Authorised” to conduct MDSAP audits
under the Pilot arrangements – 1st MDSAP audit by the AO is witnessed then all assessment material is reviewed to confirm
continued Authorisation. – A minimum of 2 additional MDSAP audits are to be performed and witnessed to meet the
minimum recognition criteria
– Regulatory Authorities will announce the successful Auditing Organisations at the Pilot and grant them full MDSAP Auditing Organisation Recognition.
27
Facts: Assessment activities • Application Review: 13 • Stage 1 Assessment: 10 • Stage 2 Assessment: 10 • Critical Locations: 5 • Witnessed Audit: 11 • Surveillance Assessment: 7 • Special Assessment: 1
28
Auditing organisations and the MDSAP Pilot • During the Pilot, only the Auditing
Organisations recognized under the Canadian CMDCAS program were allowed to participate. – All 13 have applied and are progressing
through the stages of assessment – Others will be allowed to apply from 1
January 2017 – See “AO Availability” for an updated listing
on MDSAP website.
• BSI Group America • TUV SUD America Inc. • Intertek Testing Services • LNE G-MED • SAI Global Certification Services • TUV USA Inc. • LRQA • DQS Med • DEKRA Certification B.V. • TUV Rheinland N.A. Inc. • NSAI • SGS UK Ltd. • UL, LLC 29
MDSAP Participation
30
Participating manufacturers (June 2016)
6 9 10 25
11 23 24
106 15
25
50 61
83
107 117
0
20
40
60
80
100
120
140
Sites Added
Cumulative Total
Q3, Q1, Q2, Q3, Q4, Q1, Q2, July, 2014 2015 2015 2015 2015 2016 2016 2016
31
Profile of manufacturers currently participating
• Organisations selling into Canada and internationally • Manufacturing sites for finished medical devices • Relatively large organisations
– ~ 70 people and more
• Manufacturers of combination products selling into Australia • Organisations intending to sell in Brazil • Manufacturers of high risk medical devices • Organisations participating in the WHO Prequalification of IVDs Program
32
Why should manufacturers participate? • Limit the number of medical device regulatory audits • Improvement in predictability of audit outcomes • Facilitate the application for marketing authorisation in countries where a quality
management system audit is a prerequisite • Anticipate the transition towards the mandatory application of MDSAP in Canada
• Be a part of the process during the pilot to help shape the policies and procedures for the operational program scheduled to begin in 2017
• Encourage the Auditing Organisation to get authorized/ recognized • As MDSAP grows, so will RA participation • Choice of MDSAP Auditing Organisation
33
Some RA-specific benefits • Australia – TGA will take into account MDSAP audit reports for QMS when:
– deciding whether to issue or maintain Conformity Assessment Certificates that are required for “combination” products Medicine / Device, Animal Origin / Device etc.
– auditing applications for ARTG Entry when evidence of compliance with the QMS requirements of a conformity assessment procedure is required.
– when EC Conformity Assessment Certification for QMS is not available.
• Brazil – program outcomes and reports used as key inputs into ANVISA’s premarket and post-market assessment procedures
34
Some RA-specific benefits • Canada – will accept either MDSAP or CMDCAS certificates for obtaining Class
II, III or IV medical device license. Full transition to MDSAP expected to occur by 2019
• Japan – may accelerate the Marketing Authorisation and reduce post-market burden (still under evaluation)
• United States – will accept MDSAP audit reports as substitute for routine inspections
• See also MDSAP Question and Answer document on FDA MDSAP website! 35
WHO Prequalification for diagnostic devices
• MDSAP audits may be recognized as acceptable evidence of QMS compliance with international regulations, resulting in an abbreviated or waived site audit by WHO.
36
How to participate • Any medical device manufacturer is eligible • Participation is not initiated through a Regulatory Authority! • Identify a participating MDSAP Auditing Organisation - FDA MDSAP website.
– Any current CMDCAS recognized registrar – Many may also be able to provide audit and assessment for EC Certification.
• Inquire if the AO has progressed sufficiently in the assessment process to accept applications for an MDSAP audit.
• An RA’s routine audit / inspection program will not be suspended until an AO notifies MDSAP of a manufacturer’s participation in the program. – Note that “for cause” audits may still be conducted by RAs
37
Feedback mechanisms • IMDRF Consultations
• MDSAP Participation Surveys
• Email: – MDSAP@tga.gov.au – MDSAP.ATENDIMENTO@anvisa.gov.br – QS_MDB_HC@hc-sc.gc.ca – MDSAP@pmda.go.jp – MDSAP@fda.hhs.gov
38
Resources – MDSAP Website http://www.fda.gov/medicaldevices/internationalprograms/mdsappilot/default.htm
– MDSAP Question and Answer Document http://www.fda.gov/downloads/MedicalDevices/InternationalPrograms/MDSAPPilot/UCM430563.pdf
– Canadian Medical Device Conformity Assessment System (CMDCAS)-Recognized Certification Bodies http://www.scc.ca/accreditation/management-systems/cmdcas/cmdcas-recognized-certification-bodies
– IMDRF Consultations http://www.imdrf.org/consultations/consultations.asp#current
39
Resources • CDRH Learn:
– http://www.fda.gov/Training/CDRHLearn/ucm372921.htm
• MDSAP Documents: – http://www.fda.gov/MedicalDevices/InternationalPrograms/MDSAPPilot/default.htm
• IMDRF Final Documents: – http://www.imdrf.org/documents/documents.asp
40
41
Questions
top related